IPP Bureau
Health Minister Nadda reviews Monkeypox situation and preparedness
By IPP Bureau - August 19, 2024
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
Health Ministry assures doctors of all possible efforts to ensure safety
By IPP Bureau - August 19, 2024
A committee to be formed to suggest measures for ensuring the safety of healthcare professionals
CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance
By IPP Bureau - August 19, 2024
The emergence of new infections in India is a growing concern
ANVISA completes inspection at Caplin Steriles' facility at Gummidipoondi
By IPP Bureau - August 19, 2024
Zydus Lifesciences to scale up US specialties business
By IPP Bureau - August 19, 2024
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Allozymes partners with Adisseo on next-gen animal feed production
By IPP Bureau - August 19, 2024
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP
By IPP Bureau - August 19, 2024
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
EMA validates Bristol Myers Squibb’s application for CAR T cell therapy Breyanzi for relapsed or refractory follicular lymphoma
By IPP Bureau - August 19, 2024
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Aptar’s nasal unidose system delivers FDA-approved neffy
By IPP Bureau - August 19, 2024
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Lupin receives USFDA’s tentative approval for Brimonidine Tartrate Ophthalmic Solution
By IPP Bureau - August 17, 2024
Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC) is indicated to relieve redness of the eye due to minor eye irritations.
Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer
By IPP Bureau - August 17, 2024
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
Fortis Hospital Mulund hosts India's first IFEM endorsed ECMO workshop for emergency medicine doctors
By IPP Bureau - August 16, 2024
This two-day program was attended by 40 doctors & paramedical staff
Apollo Hospitals Chennai reaches 6,000+ successful robotic procedure
By IPP Bureau - August 16, 2024
The robotic surgery program has continually pushed the boundaries of medical technology
Pfizer and BioNTech update on mRNA-based combination vaccine program against Influenza and Covid-19
By IPP Bureau - August 16, 2024
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
